Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. [electronic resource]
Producer: 20040805Description: 81-4 p. digitalISSN:- 0167-8140
- Administration, Oral
- Antimetabolites, Antineoplastic -- administration & dosage
- Capecitabine
- Carcinoma, Squamous Cell -- drug therapy
- Combined Modality Therapy
- Deoxycytidine -- administration & dosage
- Drug Evaluation
- Fluorouracil -- analogs & derivatives
- Humans
- Mucous Membrane
- Otorhinolaryngologic Neoplasms -- drug therapy
- Prodrugs -- therapeutic use
- Radiation Injuries -- prevention & control
- Radiation-Sensitizing Agents -- administration & dosage
- Radiotherapy Dosage
- Stomatitis -- diagnosis
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.